NanoVibronix Announces Interim Results of Clinical Study for UroShield

Author's Avatar
Nov 16, 2022

%3Cb%3ENanoVibronix%2C+Inc%3C%2Fb%3E., (NASDAQ: NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced interim results of its U.K. clinical study for UroShield that is being conducted by The University of Southampton and the National Biofilms Innovation Centre.